Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy

Supportive Care in Cancer

Volumn 8, Issue 3, 2000, Pages 233-237

  Sigsgaard, Tine ^a   Herrstedt, Jørn ^a   Christensen, Pia ^a   Andersen, Odette ^a   Dombernowsky, Per ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Granisetron; Metopimazine; Multiple cycles; Prednisolone; Refractory emesis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUOROURACIL; GRANISETRON; METHOTREXATE; METOPIMAZINE; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART PALPITATION; HEARTBURN; HUMAN; NAUSEA; PRIORITY JOURNAL; VERTIGO; VOMITING;

EID: 0034109610     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050291     Document Type: Article

References (21)

1. Griffin AM, Butow PN, Coates AS, et al (1996) On the receiving end V: Patient perception of the side effects of cancer. Ann Oncol 7:189-195
2. Roila F, Tonato M, Basurto C, et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7:1693-1700
3. Strum SB, McDermed JE, Pileggi J, Riech LP, Whitaker H (1984) Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. Cancer 53:1432-1439
4. Italian Group for Antiemetic Research (1995) Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 13:2417-2426
5. Italian Group for Antiemetic Research (1994) Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Support Care Cancer 2:167-170
6. Bruera ED, Roca E, Cedaro L, Chacón R, Estévez R (1983) Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 67:381-383
7. Campora E, Vidili G, Oliva C, Ardizzoni A, Rosso R (1991) Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F). Oncology 48:403-405
8. Smith DB, Newlands ES, Spruyt OW, et al (1990) Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 61:323-324
9. Cunningham D, Turner A, Hawthorn J, Rosin RD (1989) Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet I:1323
10. Hulstaert F, Van Belle S, Bleiberg H, et al (1994) Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting. J Clin Oncol 12:2439-2446
11. Plezia PM, Alberts DS, Kessler J. Aapro M, Graham V, Surwit EA (1984) Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen. Cancer Treat Rep 68:1493-1495
12. Sigsgaard T, Herrstedt J, Andersen LJ, et al (1999) Granisetron compared with prednisolone plus metopimazine as antiemetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer 80:412-418
13. Jones A, Hill AS, Soukop M, et al (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338:483-487
14. The Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5
15. Kaasa S, Kvaløy S, Dicato MA, et al (1990) A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 26:311-314
16. Bonneterre J, Chevallier B, Metz R, et al (1990) A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8:1063-1069
17. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B (1991) Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubucin and cyclophosphamide. Eur J Cancer 27:1137-1140
18. 3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26 [Suppl 1]:S28-S32
19. Warr D, Willan A, Fine S, et al (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83:1169-1173
20. Kirchner V, Aapro M, Terrey JP, Alberto P (1997) A double-blind cross-over study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy. Eur J Cancer 33:1605-1610
21. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328:1076-1080